Literature DB >> 21959070

Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma.

Alka Kriplani1, Divya Awasthi, Vidushi Kulshrestha, Nutan Agarwal.   

Abstract

OBJECTIVE: To evaluate the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) in reducing menstrual blood loss (MBL) in myoma-related menorrhagia and to assess the effect of the LNG-IUS on uterine and leiomyoma volume.
METHODS: A prospective comparative study investigated the effect of LNG-IUS use in women with myoma-related menorrhagia (n=54) and women with idiopathic menorrhagia (n=50). The outcome was assessed in terms of reductions in MBL and in myoma and uterine volume.
RESULTS: Within 1 month of LNG-IUS insertion, the Pictorial Blood Loss Assessment Chart score in the myoma group fell by 86.8% (P<0.0001). At 3, 12, 24, 36, and 48 months, the MBL was reduced by 92.1%, 97.4%, 97.4%, 99.5%, and 99.5%, respectively, similar to the effect seen in the idiopathic menorrhagia group. The mean uterine volume was significantly reduced in both groups, but the reduction was greater in the group with leiomyomas (idiopathic menorrhagia, P=0.038; myoma-related menorrhagia, P=0.012). There was no statistically significant reduction in the myoma volume (P=0.409).
CONCLUSION: Use of the LNG-IUS appears to lead to a significant reduction in the uterine volume of women with menorrhagia, as well as reducing the MBL in women with uterine leiomyomas.
Copyright © 2011 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959070     DOI: 10.1016/j.ijgo.2011.07.031

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  10 in total

1.  Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).

Authors:  Ussanee S Sangkomkamhang; Pisake Lumbiganon; Porjai Pattanittum
Journal:  Cochrane Database Syst Rev       Date:  2020-11-23

Review 2.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

3.  Treatment for Uterine Fibroids: Searching for Effective Drug Therapies.

Authors:  Darlene K Taylor; Phyllis C Leppert
Journal:  Drug Discov Today Ther Strateg       Date:  2012

4.  Abnormal uterine bleeding in midlife: The role of levonorgestrel intrauterine system.

Authors:  Osama Shawki; Amr Wahba; Navneet Magon
Journal:  J Midlife Health       Date:  2013-01

5.  Levonorgestrel intrauterine system: Current role in management of heavy menstrual bleeding.

Authors:  Navneet Magon; Monica Chauhan; Poonam Goel; Sonia Malik; Krishan Kapur; Alka Kriplani; Lakhbir Dhaliwal; Suchitra N Pandit
Journal:  J Midlife Health       Date:  2013-01

Review 6.  Pharmacological treatment of uterine fibroids.

Authors:  Rm Moroni; Cs Vieira; Ra Ferriani; Fj Candido-Dos-Reis; Lgo Brito
Journal:  Ann Med Health Sci Res       Date:  2014-09

Review 7.  Current medical treatment of uterine fibroids.

Authors:  Geum Seon Sohn; SiHyun Cho; Yong Man Kim; Chi-Heum Cho; Mee-Ran Kim; Sa Ra Lee
Journal:  Obstet Gynecol Sci       Date:  2018-02-13

8.  Predictive factors for failure of the levonorgestrel releasing intrauterine system in women with heavy menstrual bleeding.

Authors:  Pleun Beelen; Marian J van den Brink; Malou C Herman; Peggy M Geomini; Ruben G Duijnhoven; Marlies Y Bongers
Journal:  BMC Womens Health       Date:  2021-02-09       Impact factor: 2.809

Review 9.  Menstrual suppression: current perspectives.

Authors:  Paula Adams Hillard
Journal:  Int J Womens Health       Date:  2014-06-23

Review 10.  The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids.

Authors:  Wojciech Wrona; Anna Stępniak; Piotr Czuczwar
Journal:  Prz Menopauzalny       Date:  2017-12-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.